



REVIEW ARTICLE

Nanoparticles: Emerging carriers for drug delivery

Sagar R. Mudshinge ^a, Amol B. Deore ^b, Sachin Patil ^c, Chetan M. Bhalgat ^{d,*}

^a NDMVP's College of Pharmacy, Nashik 422005, Maharashtra, India

^b NDMVP's Institute of Pharmaceutical Sciences, Adgaon, Nashik, Maharashtra, India

^c Mayani College of Pharmacy, Mayani, Satara Dist., Maharashtra, India

^d S.A.C. College of Pharmacy, B.G. Nagara 571448, Nagamangala (Tq), Mandya Dist., Karnataka, India

Received 9 February 2011; accepted 12 April 2011

Available online 21 April 2011

KEYWORDS

Nanoparticles;
Nanoscale;
Biomacromolecular;
Supramolecular;
Diagnostics;
Nanostructures

Abstract The core objective of nanoparticles is to control and manipulate biomacromolecular constructs and supramolecular assemblies that are critical to living cells in order to improve the quality of human health. By definition, these constructs and assemblies are nanoscale and include entities such as drugs, proteins, DNA/RNA, viruses, cellular lipid bilayers, cellular receptor sites and antibody variable regions critical for immunology and are involved in events of nanoscale proportions. The emergence of such nanotherapeutics/diagnostics will allow a deeper understanding of human longevity and human ills that include cancer, cardiovascular disease and genetic disorders. A technology platform that provides a wide range of synthetic nanostructures that may be controlled as a function of size, shape and surface chemistry and scale to these nanotechnical dimensions will be a critical first step in developing appropriate tools and a scientific basis for understanding nanoparticles.

© 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.

Contents

1. Nanoparticles	130
2. Drug release from nanoparticles	130


* Corresponding author. Tel.: +91 9241752830; fax: +91 8234287242.

E-mail address: chetanbhalgat2004@yahoo.co.in (C.M. Bhalgat).

1319-0164 © 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.

Peer review under responsibility of King Saud University.

doi:10.1016/j.jsps.2011.04.001



3.	Types of nanoparticles	130
3.1.	Fullerenes	130
3.2.	Solid lipid nanoparticles (SLNs)	130
3.3.	Liposomes	131
3.4.	Nanostructured lipid carriers (NLC)	132
3.5.	Nanoshells	132
3.6.	Quantum dots (QD)	133
3.7.	Superparamagnetic nanoparticles	134
3.8.	Dendrimers	136
4.	Conclusion	137
	Acknowledgements	137
	References	137

1. Nanoparticles

Conventional preparations like solution, suspension or emulsion suffer from certain limitations like high dose and low availability, first pass effect, intolerance, instability, and they exhibit fluctuations in plasma drug levels and do not provide sustained effect, therefore there is a need for some novel carriers which could meet ideal requirement of drug delivery system. Recently nanoparticles delivery system has been proposed as colloidal drug carriers. Nanoparticles (NP) are a type of colloidal drug delivery system comprising particles with a size range from 10 to 1000 nm in diameter. Nanoparticles may or may not exhibit size-related properties that differ significantly from those observed in fine particles or bulk materials (Buzea et al., 2007). The key advantages of nanoparticles are (1) improved bioavailability by enhancing aqueous solubility, (2) increasing resistance time in the body (increasing half life for clearance/increasing specificity for its cognate receptors and (3) targeting drug to specific location in the body (its site of action). This results in concomitant reduction in quantity of the drug required and dosage toxicity, enabling the safe delivery of toxic therapeutic drugs and protection of non target tissues and cells from severe side effects (Irving, 2007). It is increasingly used in different applications, including drug carrier systems and to pass organ barriers such as the blood-brain barrier, cell membrane etc (Abhilash, 2010). They are based on biocompatible lipid and provide sustained effect by either diffusion or dissolution (Cavalli et al., 1995; Müller et al., 2000; Yang et al., 1999; zur Mühlen and Mehnert, 1998).

2. Drug release from nanoparticles

The nanoparticle is coated by polymer, which releases the drug by controlled diffusion or erosion from the core across the polymeric membrane or matrix. The membrane coating acts as a barrier to release, therefore, the solubility and diffusivity of drug in polymer membrane becomes the determining factor in drug release. Furthermore release rate can also be affected by ionic interaction between the drug and addition of auxiliary ingredients. When the drug is involved in interaction with auxiliary ingredients to form a less water soluble complex, then the drug release can be very slow with almost no burst release effect (Chen et al., 1994).

To develop a successful nanoparticulate system, both drug release and polymer biodegradation are important consideration factors. In general, drug release rate depends on (1) sol-

ubility of drug, (2) desorption of the surface bound/ adsorbed drug, (3) drug diffusion through the nanoparticle matrix, (4) nanoparticle matrix erosion/degradation and (5) combination of erosion/diffusion process (Mohanraj and Chen, 2006). Thus solubility, diffusion and biodegradation of the matrix materials govern the release process.

3. Types of nanoparticles

Extensive libraries of nanoparticles, composed of an assortment of different sizes, shapes, and materials, and with various chemical and surface properties, have already been constructed. The field of nanotechnology is under constant and rapid growth and new additions continue to supplement these libraries. The classes of nanoparticles listed below are all very general and multi-functional; however, some of their basic properties and current known uses in nanomedicine are described here.

3.1. Fullerenes

A fullerene is any molecule composed entirely of carbon, in the form of a hollow sphere, ellipsoid, or tube. Spherical fullerenes are also called buckyballs, and cylindrical ones are called carbon nanotubes or buckytubes. Fullerenes are similar in structure to the graphite, which is composed of stacked grapheme sheets of linked hexagonal rings, additionally they may also contain pentagonal (or sometimes heptagonal) rings to give potentially porous molecules (Holister et al., 2003). Buckyball clusters or buckyballs composed of less than 300 carbon atoms are commonly known as endohedral fullerenes and include the most common fullerene, buckminsterfullerene, C₆₀. Megatubes are larger in diameter than nanotubes and prepared with walls of different thickness which is potentially used for the transport of a variety of molecules of different sizes (Mitchell et al., 2001). Nano “onions” are spherical particles based on multiple carbon layers surrounding a buckyball core which are proposed for lubricants (Sano et al., 2001). These properties of fullerenes hold great promise in health and personal care application. The versatile biomedical applications are enlisted in Table 1.

3.2. Solid lipid nanoparticles (SLNs)

SLNs mainly comprise lipids that are in solid phase at the room temperature and surfactants for emulsification, the mean

Table 1 Biomedical application of fullerenes.

Fullerenes composition	Application	References
Fullerene (C ₆₀)	HIV proteases	Friedman et al. (1993) and Sijbesma et al. (1993)
Fulleropyrrolidines	HIV-1 and HIV-2	Marchesan et al. (2005)
Dendrofullerene 1	HIV-1 replication	Brettreich and Hirsch (1998) and Schuster et al. (2000)
Amino acid derivatives of fullerene C60 (ADF)	HIV and human cytomegalovirus replication	Kotelnikova et al. (2003)
Buckminsterfullerene	Semliki forest virus (SFV, Togaviridae) or vesicular stomatitis virus (VSV, Rhabdoviridae)	Kaesermann and Kempf (1997)
Cationic, anionic and amino acid type fullerene	HIV-reverse transcriptase and hepatitis C virus replication	Mashino et al. (2005)
Fullerene (C ₆₀) 34 methyl radicals	Free radicals and oxidative stress	Krusic et al. (1991)
Fullerene (C ₆₀)	Liver toxicity and diminished lipid peroxidation	Slater et al. (1985)
C3-Fullero-tris-methanodicarboxylic acid	Apoptosis of neuronal cells	Dugan et al. (1997)
Carboxyfullerene	Apoptosis of hepatoma cells	Huang et al. (1998)
Carboxyfullerenes	Neurological disease including Parkinson's disease	Dugan et al. (1997)
Fullerene (C ₆₀) with organic cationic compounds, viral carriers, recombinant proteins and inorganic nanoparticles	Gene transfer	Azzam and Domb (2004)
Metallofullerol	Leukemia and bone cancer	Thrash et al. (1999)

diameters of which range from 50 nm to 1000 nm for colloid drug delivery applications (zur Mühlen et al., 1998). SLNs offer unique properties such as small size, large surface area, high drug loading, the interaction of phases at the interfaces, and are attractive for their potential to improve performance of pharmaceuticals, nutraceuticals and other materials (Cavalli et al., 1993). The typical methods of preparing SLNs include spray drying (Freitas and Müller, 1998), high shear mixing (Domb, 1993), ultra-sonication (zur Mühlen, 1996; Eldem et al., 1991), and high pressure homogenization (HPH) (Müller et al., 1996; Speiser, 1990). Solid lipids utilized in SLN formulations include fatty acids (e.g. palmitic acid, decanoic acid, and behenic acid), triglycerides (e.g. trilaurin, trimyristin, and tripalmitin), steroids (e.g. cholesterol), partial glycerides (e.g. glyceryl monostearate and glyceryl behenate) and waxes (e.g. cetyl palmitate). Several types of surfactants are commonly used as emulsifiers to stabilize lipid dispersion, including soybean lecithin, phosphatidylcholine, poloxamer 188, sodium cholate, and sodium glycocholate (Zhang et al., 2010).

Advantages of these solid lipid nanoparticles (SLN) are the use of physiological lipids, the avoidance of organic solvents in the preparation process, and a wide potential application spectrum (dermal, oral, intravenous). Additionally, improved bioavailability, protection of sensitive drug molecules from the environment (water, light) and controlled and/or targeted drug release (Mehnert and Mäder, 2001; Müller et al., 2002; Müller et al., 2000), improved stability of pharmaceuticals, feasibilities of carrying both lipophilic and hydrophilic drugs and most lipids being biodegradable (Müller and Runge, 1998; Jennings et al., 2000).

SLNs possess a better stability and ease of upgradability to production scale as compared to liposomes. This property may be very important for many modes of targeting. SLNs form the basis of colloidal drug delivery systems, which are biodegradable and capable of being stored for at least one year. There

are several potential applications of SLNs some of which are given in Table 2.

3.3. Liposomes

Liposomes are vesicular structures with an aqueous core surrounded by a hydrophobic lipid bilayer, created by the extrusion of phospholipids. Phospholipids are GRAS (generally recognised as safe) ingredients, therefore minimizing the potential for adverse effects. Solutes, such as drugs, in the core cannot pass through the hydrophobic bilayer however hydrophobic molecules can be absorbed into the bilayer, enabling the liposome to carry both hydrophilic and hydrophobic molecules. The lipid bilayer of liposomes can fuse with other bilayers such as the cell membrane, which promotes release of its contents, making them useful for drug delivery and cosmetic delivery applications. Liposomes that have vesicles in the range of nanometers are also called nanoliposomes (Zhang and Granick, 2006; Cevc, 1996). Liposomes can vary in size, from 15 nm up to several µm and can have either a single layer (unilamellar) or multiple phospholipid bilayer membranes (multilamellar) structure. Unilamellar vesicles (ULVs) can be further classified into small unilamellar vesicles (SUVs) and large unilamellar vesicles (LUVs) depending on their size range (Vemuri and Rhodes, 1995).

The unique structure of liposomes, a lipid membrane surrounding an aqueous cavity, enables them to carry both hydrophobic and hydrophilic compounds without chemical modification. In addition, the liposome surface can be easily functionalized with 'stealth' material to enhance their in vivo stability or targeting ligands to enable preferential delivery of liposomes. These versatile properties of liposomes made them to be used as potent carrier for various drugs like antibacterials, antivirals, insulin, antineoplastics and plasmid DNA (Table 3).

Table 2 Biomedical application of solid lipid nanoparticles.

SLN composition	Drug	Application	References
Stearic acid	Rifampicin, isoniazid, pyrazinamide	<i>Mycobacterium tuberculosis</i>	Pandey and Khuller (2005)
Stearic acid, soya phosphatidylcholine, and Sodium taurocholate	Ciprofloxacin hydrochloride, tobramycin	Gram-negative bacteria, grampositive bacteria and mycoplasma	Jain and Banerjee (2008)
Glyceryl tripalmitate and tyloxapol	Clotrimazole	Fungi (e.g. yeast, aspergilli, dermatophytes)	Souto et al. (2004)
Glyceryl behenate and sodium deoxycholate	Ketoconazole	Fungi	Souto and Müller (2005)
Glyceryl behenate, propylene glycol, tween 80, and Glyceryl monostearate	Miconazole nitrate	Fungi	Bhalekar et al. (2009)
Glycerol palmitostearate	Econazole nitrate	Fungi	Sanna et al. (2007)
Cetyl palmitate	Insulin	Type 1 diabetes	Sarmiento et al. (2007)
Lecithin, SODIUM taurocholate	Nimesulide	Inflammation	Jain et al. (2009a,b)
Oleic acid	Ibuprofen	Inflammation	Panga et al. (2009)
Poly(lactide) (PLA), poly(lactideco-glycolide) (PLGA), poly-ε-caprolactone (PCL) and poly(ortho esters)	Bacterial and viral antigens	Immunity	Tamber et al. (2005), Storni et al. (2005) and Yuki and Kiyono (2003)
Stearic acid, soya phosphatidylcholine, and sodium taurocholate	Tobramycin	<i>Pseudomonas aeruginosa</i>	Cavalli et al. (2002)
Soyabean-oil	Doxorubicin	Breast cancer	Wong et al. (2006)
Hyaluronic acid-coupled chitosan	Oxaliplatin	Colorectal cancer	Jain et al. (2009a,b)
Cholesteryl butyrate	Doxorubicin, paclitaxel	Colorectal cancer	Serpe et al. (2004)
SLN	Tamoxifen,	Breast cancer	Fontana et al. (2005)
SLN	Methotrexate and camptothecin	Carcinoma	Ruckmani et al. (2006) and Yang et al. (1999)

3.4. Nanostructured lipid carriers (NLC)

Nanostructured Lipid Carriers are produced from blend of solid and liquid lipids, but particles are in solid state at body temperature. Lipids are versatile molecules that may form differently structured solid matrices, such as the nanostructured lipid carriers (NLC) and the lipid drug conjugate nanoparticles (LDC), that have been created to improve drug loading capacity (Wissing et al., 2004). The NLC production is based on solidified emulsion (dispersed phase) technologies. NLC can present an insufficient loading capacity due to drug expulsion after polymorphic transition during storage, particularly if the lipid matrix consists of similar molecules.

Drug release from lipid particles occurs by diffusion and simultaneously by lipid particle degradation in the body. In some cases it might be desirable to have a controlled fast release going beyond diffusion and degradation. Ideally this release should be triggered by an impulse when the particles are administered. NLCs accommodate the drug because of their highly unordered lipid structures. A desired burst drug release can be initiated by applying the trigger impulse to the matrix to convert in a more ordered structure. NLCs of certain structures can be triggered this way (Radtke and Müller, 2001). NLCs can generally be applied where solid nanoparticles possess advantages for the delivery of drugs. Major application areas in pharmaceuticals are topical drug delivery, oral and parenteral (subcutaneous or intramuscular and intrave-

nous) route. LDC nanoparticles have proved particularly useful for targeting water-soluble drug administration. They also have applications in cosmetics, food and agricultural products. These have been utilized in the delivery of anti-inflammatory compounds, cosmetic preparation, topical cortico therapy and also increases bioavailability and drug loading capacity. Few biomedical applications of NLCs are enlisted in Table 4.

3.5. Nanoshells

Nanoshells are also notorious as core-shells, nanoshells are spherical cores of a particular compound (concentric particles) surrounded by a shell or outer coating of thin layer of another material, which is a few 1–20 nm nanometers thick (Liz-Marzan et al., 2001; Davies et al., 1998; Templeton et al., 2000; Xia et al., 2000). Nanoshell particles are highly functional materials show modified and improved properties than their single component counterparts or nanoparticles of the same size. Their properties can be modified by changing either the constituting materials or core-to-shell ratio (Oldenberg et al., 1998). Nanoshell materials can be synthesized from semiconductors (dielectric materials such as silica and polystyrene), metals and insulators. Usually dielectric materials such as silica and polystyrene are commonly used as core because they are highly stable (Kalele et al., 2006a,b).

Metal nanoshells are a novel type of composite spherical nanoparticles consisting of a dielectric core covered by a thin

Liposome composition	Drug	Application	References
Hydrogenated soya, phosphatidylcholine, cholesterol and distearoylphosphatidylglycerol (DSPG)	Amphotericin B	<i>Aspergillus fumigatus</i>	Takemoto et al. (2004)
1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and cholesterol	Polymyxin B	<i>Pseudomonas aeruginosa</i>	Omri et al. (2002)
Hydrogenated Soya phosphatidylcholine (PC) and cholesterol	Ampillicin	<i>Micrococcus luteus</i> and <i>Salmonella typhimurium</i>	Schumacher and Margalit (1997)
Dipalmitoyl-phosphatidylcholine, dipalmitoyl-phosphatidylglycerol and cholesterol	Ciprofloxacin	<i>Salmonella dublin</i>	Magallanes et al. (1993)
Dipalmitoyl-phosphatidylcholine (DPPC), cholesterol and dimethylammonium ethane carbamoyl cholesterol (DC-chol)	Benzyl penicillin	<i>Staphylococcus aureus</i>	Kim and Jones (2004)
Phosphatidylcholine, cholesterol and phosphatidylinositol	Netilmicin	<i>Bacillus subtilis</i> and <i>Escherichia coli</i>	Mimoso et al. (1997)
Partially hydrogenated egg phosphatidylcholine (PHEPC), cholesterol and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(polyethylene glycol-2000) (PEGDSPE)	Gentamicin	<i>Klebsiella pneumoniae</i>	Schiffelers et al. (2001)
Phosphatidyl glycerol, phosphatidyl choline and cholesterol	Streptomycin	<i>Mycobacterium avium</i>	Gangadharam et al. (1991)
Hydrogenated soy phosphatidylcholine, cholesterol and distearoylphosphatidylglycerol (DSPG)	Amikacin	Gram-negative bacteria	Fielding et al. (1998)
Stearylamine (SA) and dicetyl phosphate	Zidovudine	Human immunodeficiency virus	Kaur et al. (2008)
Egg phosphatidylcholine, diacetylphosphate and cholesterol	Vancomycin or teicoplanin	methicillin-resistant <i>Staphylococcus aureus</i> (MRSA)	Onyeji et al. (1994)
DC-Chol liposome	Plasmid DNA	Gene transfer in subcutaneous tumor	Whitemore et al. (2001)
Liposome	Daunorubicin and doxorubicin	Breast cancer	Park (2002)
Liposome	Anti-GD ₂ immunoliposomes, Liposomes Entrapping Fenretinide (HPR), Gold-Containing Liposomes	Neuroblastoma	Di Paolo et al. (2009)
Hepatically targeted liposomes	Insulin	Diabetes mellitus	Spangler (1990)

metallic shell which is typically gold. Nanoshells possess highly favorable optical and chemical properties for biomedical imaging and therapeutic applications. Nanoshells offer other advantages over conventional organic dyes including improved optical properties and reduced susceptibility to chemical/thermal denaturation. Furthermore, the same conjugation protocols used to bind biomolecules to gold colloid are easily modified for nanoshells (Loo et al., 2004). When a nanoshell and polymer matrix is illuminated with resonant wavelength, nanoshells absorb heat and transfer to the local environment. This causes collapse of the network and release of the drug. In core shell particles-based drug delivery systems either the drug can be encapsulated or adsorbed onto the shell surface (Sparnacci et al., 2002). The shell interacts with the drug via a specific functional group or by electrostatic stabilization method. When it comes in contact with the biological system, it directs the drug. In imaging applications, nanoshells can be tagged with specific antibodies for diseased tissues or tumors. Nanoshell materials have received considerable attention in recent years because of potential applications associated with them. A few applications in the area of imaging and diagnostics are discussed in Table 5.

3.6. Quantum dots (QD)

The quantum dots are semiconductor nanocrystals and core-shell nanocrystals containing interface between different semiconductor materials. The size of quantum dots can be continuously tuned from 2 to 10 nm, which, after polymer encapsulation, generally increases to 5–20 nm in diameter. Particles smaller than 5 nm are quickly cleared by renal filtration (Choi et al., 2007a,b). Semiconductor nanocrystals have unique and fascinating optical properties, become an indispensable tool in biomedical research, especially for multiplexed, quantitative and long-term fluorescence imaging and detection (Michalet et al., 2005; Medintz et al., 2005; Alivisatos, 2004; Smith et al., 2006). QD core can serve as the structural scaffold, and the imaging contrast agent and small molecule hydrophobic drugs can be embedded between the inorganic core and the amphiphilic polymer coating layer. Hydrophilic therapeutic agents including small interfering RNA (siRNA) and antisense oligodeoxynucleotide (ODN)) and targeting biomolecules such as antibodies, peptides and aptamers can be immobilized onto the hydrophilic side of the amphiphilic polymer via either covalent or non-covalent bonds. This fully integrated nanostructure

Table 4 Biomedical application of nonstructured lipid carriers (NLC).

Nanostructured lipid carrier's composition	Application	References
Phosphatidylcholine, dynasan and flurbiprofen	Sustained release of anti-inflammatory drug	Bhaskar et al. (2009)
Stearic acid, oleic acid, carbapol and minoxidil	Pharmaceutical, cosmetic and biochemical purposes	Silva et al. (2009)
Fluticasone propionate, glyceryl palmito-stearate and PEG	Topical corticotherapy	Doktorovová et al. (2010)
Beta-carotene loaded Propylene glycol monostearate	Evaluate the feasibility	Hentschel et al. (2008)
Monostearin and caprylic and capric triglycerides	Improved drug loading capacity and controlled release properties	Hu et al. (2006)
Clozapine, triglycerides (trimyristin, tripalmitin and tristearin), soylcithin 95% and poloxamer 188)	Improved bioavailability	Venkateswarlu and Manjunath (2004)

Table 5 Biomedical application of nanoshells.

Nanoshell's composition	Applications	References
Silica coating of silver colloids	Stability of colloids	Ung et al. (1998)
Gold nanoshell	Detection of DNA	Thaxton et al. (2005)
Gold nanoshell	Immunoassay to detect analytes	Hirsch et al. (2003a)
Nanoshell	To detect cancer cells	Loo et al. (2004)
Nanoshell	To detect tumors	Hirsch et al. (2003b)
Silica-silver core-shell particles	To detect antibodies	Kalele et al. (2005)
Silver nanoshell	To detect microorganisms	Kalele et al. (2006b)
Silver nanoshells	Detection of toxic ions such as Cd, Hg and Pb present in water	Kalele et al. (2006a)
Gold nanoshells particles conjugated with enzymes and antibodies embedded in the polymer like Nisopropylacrylamide and acrylamide	Imaging of the diseases	Sparnacci et al. (2002)

may behave like magic bullets that will not only identify, but bind to diseased cells and treat it. It will also emit detectable signals for real-time monitoring of its trajectory (Qi and Gao, 2008). These benefits enable applications of QDs in medical imaging and disease detection (Table 6).

3.7. Superparamagnetic nanoparticles

Superparamagnetic molecules are those that are attracted to a magnetic field but do not retain residual magnetism after the field is removed. Nanoparticles of iron oxide with diameters in the 5–100 nm range have been used for selective magnetic bioseparations. Typical techniques involve coating the particles with antibodies to cell-specific antigens, for separation from the surrounding matrix.

The main advantages of superparamagnetic nanoparticles are that they can be visualized in magnetic resonance imaging (MRI) due to their paramagnetic properties; they can be guided to a location by the use of magnetic field and heated by magnetic field to trigger the drug release (Irving, 2007).

Superparamagnetic nanoparticles belong to the class of inorganic based particles having an iron oxide core coated by either inorganic materials (silica, gold) and organic (phospholipids, fatty acids, polysaccharides, peptides or other surfactants and polymers) (Gupta and Curtis, 2004; Babic et al.,

2008; Euliss et al., 2003). In contrast to other nanoparticles, superparamagnetic nanoparticles based on their inducible magnetization, their magnetic properties allow them to be directed to a defined location or heated in the presence of an externally applied AC magnetic field. These characteristics make them attractive for many applications, ranging from various separation techniques and contrast enhancing agents for MRI to drug delivery systems, magnetic hyperthermia (local heat source in the case of tumor therapy), and magnetically assisted transfection of cells (Horák, 2005; Gupta and Gupta, 2005; Jordan et al., 2001; Neuberger et al., 2005).

Already marketable products, so-called beads, are micron sized polymer particles loaded with SPIONs. Such beads can be functionalized with molecules that allow a specific adsorption of proteins or other biomolecules and subsequent separation in a magnetic field gradient for diagnostic purposes. More interesting applications, like imaging of single cells or tumors, delivery of drugs or genes, local heating and separation of peptides, signaling molecules or organelles from a single living cell or from a living (human) body are still subjects of intensive research. The transdisciplinarity of basic and translational research carried out in superparamagnetic nanoparticles during the last decades lead to a broad field of novel applications for superparamagnetic nanoparticles. There are several potential applications of superparamagnetic nanoparticles

Quantum dot's composition	Applications	References
Quantum dots	For measuring protein conformational changes, monitoring protein interactions, assaying of enzyme activity, in Fluorescence resonance energy transfer (FRET) technologies, particularly when conjugated to biological molecules, including antibodies, for use in immunoassays	Heyduk (2002), Day et al. (2001), Li and Bugg (2004), Kagan et al. (1996), Willard et al. (2001), Wang et al. (2002) Hohng and Ha (2005)
QD-conjugated oligonucleotide sequences (attached via surface carboxylic acid groups)	Gene technology	Pathak et al. (2001) and Gerion et al. (2002)
Conjugation of quantum dot with Tat protein, and by encapsulation in cholesterol-bearing pullulan (CHP) modified with amine groups coating with a silica shell	Fluorescent labeling of cellular proteins and different intracellular structures	Hasegawa et al. (2005) and Derfus et al. (2004)
QDs encapsulated in phospholipid micelles	Cell tracking and color imaging of live cells	Dubertret et al. (2002) and Jaiswal et al. (2003)
Transferrin-bound QDs, wheat germ agglutinin and transferrin-bound QDs, p53 conjugated with QDs	Pathogen and toxin detection such as <i>Cryptosporidium parvum</i> and <i>Giardia lamblia</i> , <i>Escherichia coli</i> 0157:H7 and <i>Salmonella typhi</i> , Hepatitis B and C viruses and <i>Listeria monocytogenes</i>	Lee et al. (2004), Zhu et al. (2004), Yang and Li (2006), Gerion et al. (2003), Agrawal et al. (2005), Goldman et al. (2002)
PEG-encapsulated QDs	In vivo animal imaging, Lymph node mapping	Gao et al. (2004), Jakub et al. (2003), Lim et al. (2003)
Quantum dots	Barriers to use in vivo	Akerman et al. (2002)
Combination of QD imaging with second-harmonic generation (SHG), CdTe bound QDs	Tumor biology investigation, Cell motility and metastatic potential, measurement of different cancer antigens	Choi et al. (2007), Parak et al. (2002), Ghazani et al. (2006), Williams et al. (2001)

Superparamagnetic nanoparticle's composition	Applications	References
SPIOs coated with organic molecules showing an overall median diameter of less than 50–160 nm	MRI contrast agents for detecting liver tumors	Smith et al. (2007)
Superparamagnetic iron oxide nanoparticles	Identify dangerous arteriosclerotic plaques by MRI	Zur Mühlen et al. (2007) and Smith et al. (2007)
Superparamagnetic Iron oxide nanoparticles (SPIOs) coated with polyvinylbenzyl- <i>O</i> - β -D-galactopyranosyl-D-gluconamide (PVLGA) with galactose moieties	Liver-targeting MRI contrast agent	Yoo et al. (2007)
Superparamagnetic iron oxide nanoparticles conjugated to luteinizing hormone releasing hormone (LHRH-SPIOs),	Enhanced MRI contrast in breast cancer xenografts and metastases in the lungs	Meng et al. (2009)
Superparamagnetic iron oxide nanoparticles	Magnetic particle imaging	Minard (2009)
Combidex a ultrasmall superparamagnetic iron oxide (USPIO) covered covered dextran	Molecular imaging agent during contrast-enhanced MRI	McIlwain (2008)
Monocrystalline iron oxide nanoparticles-47 [MION-47]	Measures macrophage burden in atherosclerosis	Morishige et al. (2010)
Colloidal dispersions of superparamagnetic (subdomain) iron oxide nanoparticles	Magnetic fluid hyperthermia (MFH) in cancer treatment	Jordan et al. (1999)
Nanosized superparamagnetic nanoparticles (Fe ₃ O ₄) coated with the multivalent cationic agent, polyethylenimine (PEI)	Purification of plasmid DNA from bacterial cells	Chiang et al. (2005)

some of which are given in Table 7. The following issues are not yet fully understood such as (1) the mechanisms utilized by cells to take up multifunctional SPIOs in human cells in culture, (2) are there membrane molecules involved?, (3) spe-

cific adsorption of SPIOs to targeted subcellular components after uptake, transport of drugs, plasmids or other substances to specific cells followed by controlled release, (4) separation of SPIOs from the cells after cell-uptake and specific adsorption

Table 8 Biomedical application of dendrimers.

Dendrimers composition	Drug	Application	References
PAMAM (polyamidoamine)	Chelated gadolinium	Diagnose certain disorders of the heart, brain and blood vessels	Wiener et al. (1994)
Poly(L-glutamic acid), polyamidoamine and poly(ethyleneimine)	Folic acid	Breast cancer	Wiener et al. (1997) and Kukowska-Latallo et al. (2005)
PAMAM	Antibodies specific to CD14 and PSMA	Cell binding and internalization	Thomas et al. (2004)
PAMAM	Sulfamethoxazole	Strep throat (<i>Streptococcus</i>), staph infection (<i>Staphylococcus aureus</i>), and flu (<i>Haemophilus influenza</i>)	Ma et al. (2007) and Abeylath et al. (2008)
PAMAM (polyamidoamine)	Nadifloxacin, prulifloxacin,	Various bacteria	Cheng et al. (2007b)
PAMAM (Polyamidoamine) PPI (polypropyleneimine generation)	Nystatin and Terbinafine	Antifungal against <i>Candida albicans</i> , <i>Aspergillus niger</i> and <i>Sachromyces cerevasae</i>	Khairnar et al. (2010)
PAMAM (polyamidoamine)	Propranolol	Hypertension	D'Emanuele et al. (2004)
Polyamidoamine (PAMAM) dendrimers	Niclosmide	Tapeworm	Devarakonda et al. (2005)
Pegylated lysine based copolymeric dendrimer	Artemether	<i>Plasmodium falciparum</i>	Bhadra et al. (2005)
PAMAM dendrimers with carboxylic or hydroxyl surface groups	Pilocarpine	Glaucoma	Vandamme and Brobeck (2005) and Tolia et al. (2008)
PAMAM	Enoxaparin	Pulmonary embolism	Bai et al. (2007)
PAMAM	Ketoprofen, Diflunisal	Inflammation	Cheng et al. (2007a)
PAMAM	Indomethacin	Inflammation	Chauhan et al. (2003)
Polylysine dendrimer	VivaGel (SPL7013 Gel)	HIV, HSV and sexually transmitted infections	Rupp et al. (2007)
Dendrimer	High resolution X-ray image	Diagnostic tool for arteriosclerotic vasculature, tumors, infarcts, kidneys or efferent urinary	Schumann et al. (2003)
Dendrimer	Gene transfer of cytokine genes (tumor necrosis factor, interleukin-2, granulocyte-macrophage colony-stimulating factor)	Induce a systemic antitumor immune response against residual tumor cells	Culver (1994)
PAMAM	5-Fluorouracil	Tumor	Zhuo et al. (1999)
Dendrimer	Isotope of boron (^{10}B)	Cancer	Hawthorne (1993)

to sub cellular components or to biomolecules like proteins without interfering with cell function, (5) prevention of uncontrolled agglomeration of modified SPIONs in physiological liquids, (6) short and long-term impact on cell functions by loading cells of different phenotypes with such nanoparticles (Hofmann-Antenbrink et al., 2009).

3.8. Dendrimers

Dendrimers are unimolecular, monodisperse, micellar nanostructures, around 20 nm in size, with a well-defined, regularly branched symmetrical structure and a high density of functional end groups at their periphery. The structure of dendrimers consists of three distinct architectural regions as a focal moiety or a core, layers of branched repeat units emerging from the core, and functional end groups on the outer layer of repeat units. They are known to be robust, covalently fixed, three dimensional structures possessing both a solvent-filled interior core (nanoscale container) as well as a homogenous, mathematically defined, exterior surface functionality (Grayson and Frechet, 2001; Svenson and Tomalia, 2005).

Dendrimers are generally prepared using either a divergent method or a convergent one (Hodge, 1993) with an architecture like a tree branching out from a central point.

Dendrimeric vectors are most commonly used as parenteral injections, either directly into the tumor tissue or intravenously for systemic delivery (Tomalia et al. 2007). Dendrimers used in drug delivery studies typically incorporate one or more of the following polymers: polyamidoamine (PAMAM), melamine, poly L-glutamic acid (PG), polyethyleneimine (PEI), polypropyleneimine (PPI), and polyethylene glycol (PEG), Chitin. Dendrimers may be used in two major modalities for targeting vectors for diagnostic imaging, drug delivery, gene transfection also detection and therapeutic treatment of cancer and other diseases, namely by (1) passive targeting-nanodimension mediated via EPR (enhanced permeability retention) effect (Matsumura and Maeda, 1986) involving primary tumor vascularization or organ-specific targeting (Kobayashi and Brechbiel, 2003) and (2) active targeting-receptor-mediated cell-specific targeting involving receptor-specific targeting groups (Hofmann-Antenbrink et al., 2009). There are several potential applications of dendrimers in the field of imaging,

drug delivery, gene transfection and non-viral gene transfer. Few applications are enrolled in Table 8.

4. Conclusion

There is a wide range of nanoparticulate materials and structures being developed for the delivery of therapeutic compounds. Each has its own particular advantages, but as these nanoparticles become optimized for their specific application, the outcome will be better-controlled therapy as a result of targeted delivery of smaller amounts of effective drugs to the required sites in the body. This is being made possible through the use of advanced material, improved control of particle size, and better understanding of interface between the biological and material surfaces, and their effects in vivo. Some nanoparticle based products are already approved by the US FDA, several others are currently under development and clinical assessment.

Acknowledgements

C.B. thanks Dr. B. Ramesh, Principal, S.A.C. College of Pharmacy, B.G. Nagara, for providing digital library for referencing and also thanks to Dr. V. Jaishree, Dr. N.K. Sathish and Dr. Md. Gulzar Ahmed for their valuable discussion.

References

- Abeylath, S.C., Tuross, E., Dickey, S., Lim, D.V., 2008. Glyconanobiotics: novel carbohydrate nanoparticle antibiotics for MRSA and Bacillus anthracis. *Bioorg. Med. Chem.* 16 (5), 2412–2418.
- Abhilash, M., 2010. Potential applications of Nanoparticles. *Int. J. Pharm. Bio Sci.* 1 (1), 1–12.
- Agrawal, A., Tripp, R.A., Anderson, L.J., Nie, S.M., 2005. Real-time detection of virus particles and viral protein expression with two-color nanoparticle probes. *J. Virol.* 79 (13), 8625–8628.
- Akerman, M.E., Chan, W.C.W., Laakkonen, P., Bhatia, S.N., Ruoslahti, E., 2002. Nanocrystal targeting in vivo. *Proc. Natl. Acad. Sci. USA* 99 (20), 12617–12621.
- Alivisatos, P., 2004. The use of nanocrystals in biological detection. *Nat. Biotechnol.* 22 (1), 47–52.
- Azzam, T., Domb, A.J., 2004. Current developments in gene transfection agents. *Curr. Drug Deliv.* 1 (2), 165–193.
- Babic, M., Horák, D., Trchová, M., Jendelová, P., Glogarová, K., Lesný, P., Herynek, V., Hájek, M., Syková, E., 2008. Poly(L-lysine)-modified iron oxide nanoparticles for stem cell labeling. *Bioconjug. Chem.* 19 (3), 740–750.
- Bai, S., Thomas, C., Ahsan, F., 2007. Dendrimers as a carrier for pulmonary delivery of enoxaparin, a low molecular weight heparin. *J. Pharm. Sci.* 96 (8), 2090–2106.
- Bhadra, D., Bhadra, S., Jain, N.K., 2005. Pegylated lysine based copolymeric dendritic micelles for solubilization and delivery of artemether. *J. Pharm. Pharm. Sci.* 8 (3), 467–482.
- Bhalekar, M.R., Pokharkar, V., Madgulkar, A., Patil, N., Patil, N., 2009. Preparation and evaluation of miconazole nitrate-loaded solid lipid nanoparticles for topical delivery. *AAPS Pharm. Sci. Tech.* 10 (1), 289–296.
- Bhaskar, K., Anbu, J., Ravichandiran, V., Venkateswarlu, V., Rao, Y.M., 2009. Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies. *Lipids Health Dis.* 8, 6.
- Brettreich, M., Hirsch, A., 1998. A highly water-soluble dendro[60]fullerene. *Tetrahedron Lett.* 39 (18), 2731–2734.
- Buzea, C., Pacheco, I., Robbie, K., 2007. Nanomaterials and nanoparticles: sources and toxicity. *Biointerphases* 2, MR17–MR71.
- Cavalli, R., Caputo, O., Gasco, M.R., 1993. Solid lipospheres of doxorubicin and idarubicin. *Int. J. Pharm.* 89 (1), R9–R12.
- Cavalli, R., Morel, S., Gasco, M.R., Chetoni, P., Saettone, M.F., 1995. Preparation and evaluation in vitro of colloidal lipospheres containing pilocarpine as ion pair. *Int. J. Pharm.* 117 (2), 243–246.
- Cavalli, R., Gasco, M.R., Chetoni, P., Burgalassi, S., Saettone, M.F., 2002. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. *Int. J. Pharm.* 238 (1–2), 241–245.
- Cevc, G., 1996. Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. *Crit. Rev. Ther. Drug Career Syst.* 13 (3–4), 257–388.
- Chauhan, A.S., Sridevi, S., Chalasani, K.B., Jain, A.K., Jain, S.K., Jain, N.K., Diwan, P.V., 2003. Dendrimer-mediated transdermal delivery: enhanced bioavailability of indomethacin. *J. Control Rel.* 90 (3), 335–343.
- Chen, Y., McCulloch, R.K., Gray, B.N., 1994. Synthesis of albumin-dextran sulfate microspheres possessing favourable loading and release characteristics for the anti-cancer drug doxorubicin. *J. Control Rel.* 31 (1), 49–54.
- Cheng, Y., Man, N., Xu, T., Fu, R., Wang, X., Wang, X., Wen, L., 2007a. Transdermal delivery of nonsteroidal anti-inflammatory drugs mediated by polyamidoamine (PAMAM) dendrimers. *J. Pharm. Sci.* 96 (3), 595–602.
- Cheng, Y., Qu, H., Ma, M., Xu, Z., Xu, P., Fang, Y., Xu, T., 2007b. Polyamidoamine (PAMAM) dendrimers as biocompatible carriers of quinolone antimicrobials: an in vitro study. *Eur. J. Med. Chem.* 42 (7), 1032–1038.
- Chiang, C.L., Sung, C.S., Wu, T.F., Chen, C.Y., Hsu, C.Y., 2005. Application of superparamagnetic nanoparticles in purification of plasmid DNA from bacterial cells. *J. Chromat. B* 822 (1–2), 54–60.
- Choi, A.O., Cho, S.J., Desbarats, J., Lovric, J., Maysinger, D., 2007a. Quantum dot-induced cell death involves Fas upregulation and lipid peroxidation in human neuroblastoma cells. *J. Nanobiotechnol.* 5, 1–4.
- Choi, H.S., Liu, W., Misra, P., Tanaka, E., Zimmer, J.P., Ipe, B.I., Bawendi, M.G., Frangion, J.V., 2007b. Renal clearance of quantum dots. *Nat. Biotechnol.* 25 (10), 1165–1170.
- Culver, K.W., 1994. Clinical applications of gene therapy for cancer. *Clin. Chem.* 40 (4), 510–512.
- Davies, R., Schurr, G.A., Meenam, P., Nelson, R.D., Bergna, H.E., Brevett, C.A.S., Goldbaum, R.H., 1998. Engineered particle surfaces. *Adv. Mater.* 10 (15), 1264–1270.
- Day, R.N., Periasamy, A., Schaufele, F., 2001. Fluorescence resonance energy transfer microscopy of localized protein interactions in the living cell nucleus. *Methods* 25 (1), 4–18.
- D’Emanuele, A., Jevprasesphant, R., Penny, J., Atwood, D., 2004. The use of a dendrimer-propranolol prodrug to bypass efflux transporters and oral bioavailability. *J. Control. Release* 95 (3), 447–453.
- Derfus, A.M., Chan, W.C.W., Bhatia, S.N., 2004. Intracellular delivery of quantum dots for live cell labeling and organelle tracking. *Adv. Mater.* 16 (12), 961–966.
- Devarakonda, B., Hill, R.A., Liebenberg, W., Brits, M., de Villiers, M.M., 2005. Comparison of the aqueous solubilization of practically insoluble niclosamide by polyamidoamine (PAMAM) dendrimers and cyclodextrins. *Int. J. Pharm.* 304 (1–2), 193–209.
- Di Paolo, D., Loi, M., Pastorino, F., Brignole, C., Marimpietri, D., Becherini, P., Caffa, I., Zorzoli, A., Longhi, R., Gagliani, C., Tacchetti, C., Corti, A., Allen, T.M., Ponzoni, M., Pagnan, G., 2009. Liposome-mediated therapy of neuroblastoma. *Methods Enzymol.* 465, 225–249.
- Doktorovová, S., Araújo, J., Garcia, M.L., Rakovský, E., Souto, E.B., 2010. Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC). *Colloids Surf. B: Biointerf.* 75 (2), 538–542.

- Domb, A.J., 1993. Liposphere parenteral delivery system. Proc. Intl. Symp. Control Rel. Bioact. Mater. 20, 346–347.
- Dubertret, B., Skourides, P., Norris, D.J., Noireaux, V., Brivanlou, A.H., Libchaber, A., 2002. In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science 298 (5599), 1759–1762.
- Dugan, L.L., Turetsky, D.M., Du, C., Lobner, D., Wheeler, M., Almi, C.R., Shen, C.K., Luh, T.Y., Choi, D.W., Lin, T.S., 1997. Carboxyfullerenes as neuroprotective agents. Proc. Natl. Acad. Sci. USA 94 (17), 9434–9439.
- Eldem, T., Speiser, P., Hincal, A., 1991. Optimization of spray-dried and congealed lipid microparticles and characterization of their surface morphology by scanning electron microscopy. Pharm. Res. 8, 47–54.
- Euliss, L.E., Grancharov, S.G., O'Brien, S., Deming, T.J., Stucky, G.D., Murray, C.B., Held, G.A., 2003. Cooperative Assembly of Magnetic Nanoparticles and Block Copolypeptides in Aqueous Media. Nano Lett. 3 (11), 1489–1493.
- Fielding, R.M., Lewis, R.O., Moon-McDermott, L., 1998. Altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low-clearance liposomes (MiKasome). Pharm. Res. 15 (11), 1775–1781.
- Fontana, G., Maniscalco, L., Schillaci, D., Cavallaro, G., Giammona, G., 2005. Solid lipid nanoparticles containing tamoxifen characterization and *in vitro* antitumoral activity. Drug Deliv. 12 (6), 385–392.
- Freitas, C., Müller, R.H., 1998. Spray-drying of Solid lipid nanoparticles (SLNTM). Eur. J. Pharm. Biopharm. 46 (2), 145–151.
- Friedman, S.H., DeCamp, D.L., Sijbesma, R.P., Srdanov, G., Wudl, F., Kenyon, G.L., 1993. Inhibition of the HIV-1 protease by fullerene derivatives: model building studies and experimental verification. J. Am. Chem. Soc. 115 (15), 6506–6509.
- Gangadharam, P.R., Ashtekar, D.A., Ghorri, N., Goldstein, J.A., Debs, R.J., Duzgunes, N., 1991. Chemotherapeutic potential of free and liposome encapsulated streptomycin against experimental Mycobacterium avium complex infections in beige mice. J. Anti-microb. Chemother. 28 (3), 425–435.
- Gao, X.H., Cui, Y.Y., Levenson, R.M., Chung, L.W.K., Nie, S.M., 2004. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 22, 969–976.
- Gerion, D., Parak, W.J., Williams, S.C., Zanchet, D., Micheel, C.M., Alivisatos, A.P., 2002. Sorting fluorescent nanocrystals with DNA. J. Am. Chem. Soc. 124 (24), 7070–7074.
- Gerion, D., Chen, F.Q., Kannan, B., Fu, A.H., Parak, W.J., Chen, D.J., Majumdar, A., Alivisatos, A.P., 2003. Room-temperature single-nucleotide polymorphism and multiallele DNA detection using fluorescent nanocrystals and microarrays. Anal. Chem. 75 (18), 4766–4772.
- Ghazani, A.A., Lee, J.A., Klostranec, J., Xiang, Q., Dacosta, R.S., Wilson, B.C., Tsao, M.S., Chan, W.C., 2006. High throughput quantification of protein expression of cancer antigens in tissue microarray using quantum dot nanocrystals. Nano Lett. 6 (12), 2881–2886.
- Goldman, E.R., Anderson, G.P., Tran, P.T., Mattoussi, H., Charles, P.T., Mauro, J.M., 2002. Conjugation of luminescent quantum dots with antibodies using an engineered adaptor protein to provide new reagents for fluoroimmunoassays. Anal. Chem. 74 (4), 841–847.
- Grayson, S.M., Frechet, J.M., 2001. Convergent dendrons and dendrimers: from synthesis to applications. Chem. Rev. 101 (12), 3819–3868.
- Gupta, A.K., Curtis, A.S.G., 2004. Lactoferrin and ceruloplasmin derivatized superparamagnetic iron oxide nanoparticles for targeting cell surface receptors. Biomaterials 25 (15), 3029–3040.
- Gupta, A.K., Gupta, M., 2005. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26 (18), 3995–4021.
- Hasegawa, U., Nomura, S.I.M., Kaul, S.C., Hirano, T., Akiyoshi, K., 2005. Nanogel-quantum dot hybrid nanoparticles for live cell imaging. Biochem. Biophys. Res. Commun. 331 (4), 917–921.
- Hawthorne, M.F., 1993. The role of chemistry in the development of boron neutron capture therapy of cancer. Angew. Chem. 32 (7), 950–984.
- Hentschel, A., Gramdorf, S., Müller, R.H., Kurz, T., 2008. Beta-carotene-loaded nanostructured lipid carriers. J. Food Sci. 73 (2), 1–6.
- Heyduk, T., 2002. Measuring protein conformational changes by FRET/ LRET. Curr. Opin. Biotechnol. 13 (4), 292–296.
- Hirsch, L.R., Jackson, J.B., Lee, A., Halas, N.J., West, J.L., 2003a. A whole blood immunoassay using gold nanoshells. Anal. Chem. 75 (10), 2377–2381.
- Hirsch, L.R., Stafford, R.J., Bankson, J.A., Sreshen, S.R., Rivera, B., Price, R.E., Hazle, J.D., Halas, N.J., West, J.L., 2003b. Nanoshell-mediated near-infrared thermal therapy of tumours under magnetic resonance guide. Proc. Natl. Acad. Sci. USA 100 (23), 13549–13554.
- Hodge, P., 1993. Polymer science branches out. Nature 362, 18–19.
- Hofmann-Antenbrink, M., von Rechenberg, B., Hofmann, H., 2009. Superparamagnetic nanoparticles for biomedical applications. In: Nanostructured Materials for Biomedical Applications. Transworld Research Network, Kerala, India, pp. 119–149.
- Hohng, S., Ha, T., 2005. Single-molecule quantum-dot fluorescence resonance energy transfer. Chemphyschem 6 (5), 956–960.
- Holister, P., Cristina, R.V., Fullerenes, H.T., 2003. Nanoparticles, Technology White papers nr. 3, Cientifica 1–12.
- Horák, D., 2005. Magnetic microparticulate carriers with immobilized selective ligands in DNA diagnostics. Polym. 46 (4), 1245–1255.
- Hu, F.Q., Jiang, S.P., Du, Y.Z., Yuan, H., Ye, Y.Q., Zeng, S., 2006. Preparation and characteristics of monostearin nanostructured lipid carriers. Int. J. Pharm. 314 (1), 83–89.
- Huang, Y.L., Shen, C.K.F., Luh, T.Y., Yang, H.C., Hwang, K.C., Chou, C.K., 1998. Blockage of apoptotic signaling of transforming growth factor- β in human hepatoma cells by carboxyfullerene. Eur. J. Biochem. 254, 38–43.
- Irving, B., 2007. Nanoparticle drug delivery systems. Inno. Pharm. Biotechnol. 24, 58–62.
- Jain, D., Banerjee, R., 2008. Comparison of ciprofloxacin hydrochlorideloaded protein, lipid, and chitosan nanoparticles for drug delivery. J. Biomed. Mater. Res. B. Appl. Biomater. 86 (1), 105–112.
- Jain, A., Jain, S.K., Ganesh, N., Barve, J., Beg, A.M., 2009a. Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanomed. 6 (1), 179–190.
- Jain, P., Mishra, A., Yadav, S.K., Patil, U.K., Baghel, U.S., 2009b. Formulation development and characterization of solid lipid nanoparticles containing nimesulide. Int. J. Drug Deliver Technol. 1 (1), 24–27.
- Jaiswal, J.K., Mattoussi, H., Mauro, J.M., Simon, S.M., 2003. Long-term multiple color imaging of live cells using quantum dot bioconjugates. Nat. Biotechnol. 21 (1), 47–51.
- Jakub, J.W., Pendas, S., Reintgen, D.S., 2003. Current status of sentinel lymph node mapping and biopsy: facts and controversies. Oncologist 8 (1), 59–68.
- Jenning, V., Gysler, A., Schafer-Korting, M., Gohla, S., 2000. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur. J. Pharm. Biopharm. 49 (3), 211–218.
- Jordan, A., Scholz, R., Wust, P., Fähling, H., Felix, R., 1999. Magnetic fluid hyperthermia (MFH): cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles. J. Magn. Magn. 201 (1–3), 413–419.
- Jordan, A., Scholz, R., Maier-Hauff, K., Johannsen, M., Wust, P., Nadobny, J., Schirra, H., Schmidt, H., Deger, S., Loening, S., Lanksch, W., Felix, R., 2001. Presentation of a new magnetic field

- therapy system for the treatment of human solid tumors with magnetic fluid hyperthermia. *J. Magn. Magn. Mater.* 225 (1–2), 118–126.
- Kaesermann, F., Kempf, C., 1997. Photodynamic inactivation of enveloped viruses by buckminsterfullerene. *Antiviral Res.* 34 (1), 65–70.
- Kagan, C.R., Murray, C.B., Nirmal, M., Bawendi, M.G., 1996. Electronic energy transfer in CdSe quantum dot solids. *Phys. Rev. Lett.* 76 (9), 1517–1520.
- Kalele, S.A., Ashtaputre, S.S., Hebalkar, N.Y., Gosavi, S.W., Deobagkar, D.N., Deobagkar, D.D., Kulkarni, S.K., 2005. Optical detection of antibody using silica–silver core-shell particles. *Chem. Phys. Lett.* 404 (1–3), 136–141.
- Kalele, S.A., Gosavi, S.W., Urban, J., Kulkarni, S.K., 2006a. Nanoshell particles: synthesis, properties and applications. *Curr. Sci.* 91 (8), 1038–1052.
- Kalele, S.A., Kundu, A.A., Gosavi, S.W., Deobagkar, D.N., Deobagkar, D.D., Kulkarni, S.K., 2006b. Rapid detection of *Escherichia coli* using antibody conjugated silver nanoshells. *Small.* 2 (3), 335–338.
- Kaur, C.D., Nahar, M., Jain, N.K., 2008. Lymphatic targeting of zidovudine using surface-engineered liposomes. *J. Drug Target* 16 (10), 798–805.
- Khairnar, G.A., Chavan-Patil, A.B., Palve, P.R., Bhise, S.B., Mourya, V.K., Kulkarni, C.G., 2010. Dendrimers: potential tool for enhancement of antifungal activity. *Int. J. Pharm. Tech. Res.* 2 (1), 736–739.
- Kim, H.J., Jones, M.N., 2004. The delivery of benzyl penicillin to *Staphylococcus aureus* biofilms by use of liposomes. *J. Liposome Res.* 14 (3–4), 123–139.
- Kobayashi, H., Brechbiel, M.W., 2003. Dendrimer-based macromolecular MRI contrast agents: characteristics and application. *Mol. Imaging* 2 (1), 1–10.
- Kotelnikova, R.A., Bogdanov, G.N., Frog, E.C., Kotelnikov, A.I., Shtolko, V.N., Romanova, V.S., Andreev, S.M., Kushch, A.A., Fedorva, N.E., Medzhidova, A.A., Miller, G.G., 2003. Nanobionics of pharmacologically active derivatives of fullerene C₆₀. *J. Nanoparticle Res.* 5, 561–566.
- Krusic, P.J., Wasserman, E., Keizer, P.N., Morton, J.R., Preston, K.F., 1991. Radical reactions of C₆₀. *Science* 254 (5035), 1183–1185.
- Kukowska-Latallo, J.F., Candido, K.A., Cao, Z., Nigavekar, S.S., Majoros, I.J., Thomas, T.P., Balogh, L.P., Khan, M.K., Baker, J.R., 2005. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. *Cancer Res.* 65 (12), 5317–5324.
- Lee, L.Y., Ong, S.L., Hu, J.Y., Ng, W.J., Feng, Y.Y., Tan, X., Wong, S.W., 2004. Use of semiconductor quantum dots for photostable immunofluorescence labeling of *Cryptosporidium parvum*. *Appl. Environ. Microbiol.* 70 (10), 5732–5736.
- Li, J.J., Bugg, T.D., 2004. A fluorescent analogue of UDP-N-acetylglucosamine: application for FRET assay of peptidoglycan translocase II (MurG). *Chem. Commun.* 2, 182–183.
- Lim, Y.T., Kim, S., Nakayama, A., Stott, N.E., Bawendi, M.G., Frangioni, J.V., 2003. Selection of quantum dot wavelengths for biomedical assays and imaging. *Mol. Imaging* 2 (1), 50–64.
- Liz-Marzan, L.M., Correa-Duarte, M.A., Pastoriza-Santos, I., Mulvaney, P., Ung, T., Giersig, M., Kotov, N.A., 2001. Core-shell and assemblies thereof. In: Nalwa, H.S. (Ed.), *Hand Book of Surfaces and Interfaces of Materials*. Elsevier, Amsterdam, Netherlands, pp. 189–237.
- Loo, C., Lin, A., Hirsch, L., Lee, M., Barton, J., Halas, N., West, J., Drezek, R., 2004. Nanoshell-enabled photonics-based imaging and therapy of cancer. *Technol. Cancer Res. Treat.* 3 (1), 33–40.
- Ma, M., Cheng, Y., Xu, Z., Xu, P., Qu, H., Fang, Y., Xu, T., Wen, L., 2007. Evaluation of Polyamidoamine (PAMAM) dendrimers as drug carriers of antibacterial drugs using sulfamethoxazole (SMZ) as a model drug. *Eur. J. Med. Chem.* 42 (1), 93–98.
- Magallanes, M., Dijkstra, J., Fierer, J., 1993. Liposome-incorporated ciprofloxacin in treatment of murine salmonellosis. *Antimicrob. Agents Chemother.* 37 (11), 2293–2297.
- Marchesan, S., Da Ros, T., Spalluto, G., Balzarini, J., Prato, M., 2005. Anti-HIV properties of cationic fullerene derivatives. *Bioorg. Med. Chem. Lett.* 15 (15), 3615–3618.
- Mashino, T., Shimotohno, K., Ikegami, N., Nishikawa, D., Okuda, K., Takahashi, K., Nakamura, S., Mochizuki, M., 2005. Human immunodeficiency virus-reverse transcriptase inhibition and hepatitis C virus RNA-dependent RNA polymerase inhibition activities of fullerene derivatives. *Bioorg. Med. Chem. Lett.* 15 (4), 1107–1109.
- Matsumura, Y., Maeda, H., 1986. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumorotropic accumulation of proteins and the antitumor agent smancs. *Cancer Res.* 46 (12), 6387–6392.
- McIlwain, C.C., 2008. *XPharm: The Comprehensive Pharmacology*. Elsevier, Amsterdam, Netherlands, pp. 1–5.
- Medintz, I.L., Uyeda, H.T., Goldman, E.R., Mattoussi, H., 2005. Quantum dot bioconjugates for imaging, labeling and sensing. *Nat. Mater.* 4 (6), 435–446.
- Mehnert, W., Mäder, K., 2001. Solid lipid nanoparticles: production, characterization and applications. *Adv. Drug Deliver Rev.* 47 (2–3), 165–196.
- Meng, J., Fan, J., Galiana, G., Branca, R.T., Clasen, P.L., Ma, S., Zhou, J., Leuschner, C., Kumar, C.S.S.R., Hormes, J., Otit, T., Beye, A.C., Harmer, M.P., Kiely, C.J., Warren, W., Haataja, M.P., Soboyejo, W.O., 2009. LHRH-functionalized superparamagnetic iron oxide nanoparticles for breast cancer targeting and contrast enhancement in MRI. *Mat. Sci. Eng. C* 29 (4), 1467–1479.
- Michalet, X., Pinaud, F.F., Bentolila, L.A., Tsay, J.M., Doose, S., Li, J.J., Sundaresan, G., Wu, A.M., Gambhir, S.S., Weiss, S., 2005. Quantum dots for live cells, in vivo imaging, and diagnostics. *Science* 307 (5709), 538–544.
- Mimoso, I.M., Francisco, A.P.G., Cruz, M.E.M., 1997. Liposomal formulation of netilmicin. *Int. J. Pharm.* 147 (1), 109–117.
- Minard, K.R., 2009. Magnetic Particle Imaging. *Encyclopedia of Spectroscopy and Spectrometry*, second ed. Elsevier, Amsterdam, Netherlands, pp. 1426–1434.
- Mitchell, D.R., Brown Jr., R.M., Spiers, T.L., Romanovicz, D.K., Lagow, R.J., 2001. The synthesis of megatubes: new dimensions in carbon materials. *Inorg. Chem.* 40 (12), 2751–2755.
- Mohanraj, V.J., Chen, Y., 2006. Nanoparticles: a review. *Trop. J. Pharm. Res.* 5 (1), 561–573.
- Morishige, K., Kacher, D.F., Libby, P., Josephson, L., Ganz, P., Weissleder, R., Aikawa, M., 2010. High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis. *Circulation* 122 (17), 1707–1715.
- Müller, R.H., Runge, S.A., 1998. Solid lipid nanoparticles (SLN) for controlled drug delivery. In: Benita, S. (Ed.), *Submicron Emulsions in Drug Targeting and Delivery*. Harwood Academic Publishers, Amsterdam, pp. 219–234.
- Müller, R.H., Maabenb, S., Weyhersa, H., Spechtb, F., Lucksb, J.S., 1996. Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. *Int. J. Pharm.* 138 (1), 85–94.
- Müller, R.H., Mader, K., Gohla, S., 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. *Eur. J. Pharm. Biopharm.* 50 (1), 161–177.
- Müller, R.H., Radtke, M., Wissing, S.A., 2002. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. *Adv. Drug Deliver. Rev.* 54, S131–S155.
- Neuberger, T., Schöpf, B., Hofmann, H., Hofmann, M., von Rechenberg, B., 2005. Superparamagnetic nanoparticles for biomedical applications: possibilities and limitations of a new drug delivery system. *J. Magn. Magn. Mater.* 293 (1), 483–496.

- Oldenberg, S.J., Averitt, R.D., Westcott, S.L., Halas, N.J., 1998. Nanoengineering of optical resonances. *Chem. Phys. Lett.* 288 (2–4), 243–247.
- Omri, A., Suntres, Z.E., Shek, P.N., 2002. Enhanced activity of liposomal polymyxin B against *Pseudomonas aeruginosa* in a rat model of lung infection. *Biochem. Pharmacol.* 64 (9), 1407–1413.
- Onyeji, C.O., Nightingale, C.H., Marangos, M.N., 1994. Enhanced killing of methicillin-resistant *Staphylococcus aureus* in human macrophages by liposome-entrapped vancomycin and teicoplanin. *Infection* 22 (5), 338–342.
- Pandey, R., Khuller, G.K., 2005. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. *Tuberculosis (Edinb)* 85 (4), 227–234.
- Panga, X., Cui, F., Tian, J., Chen, J., Zhou, J., Zhou, W., 2009. Preparation and characterization of magnetic solid lipid nanoparticles loaded with ibuprofen. *Asian J. Pharm. Sci.* 4 (2), 132–137.
- Parak, W.J., Boudreau, R., Le Gros, M., Gerion, D., Zanchet, D., Micheel, C.M., Williams, S.C., Alivisatos, A.P., Larabell, C.A., 2002. Cell motility and metastatic potential studies based on quantum dot imaging of phagokinetic tracks. *Adv. Mater.* 14 (12), 882–885.
- Park, J.W., 2002. Liposome-based drug delivery in breast cancer treatment. *Breast Cancer Res.* 4 (3), 95–99.
- Pathak, S., Choi, S.K., Arnheim, N., Thompson, M.E., 2001. Hydroxylated quantum dots as luminescent probes for in situ hybridization. *J. Am. Chem. Soc.* 123 (17), 4103–4104.
- Qi, L., Gao, X., 2008. Emerging application of quantum dots for drug delivery and therapy. *Expert Opin. Drug Deliv.* 5 (3), 63–67.
- Radtke, M., Müller, R.H., 2001. Novel concept of topical cyclosporine delivery with supersaturated SLN™ creams. *Int. Symp. Control Rel. Bioact. Mater.* 28, 470–471.
- Ruckmani, K., Sivakumar, M., Ganeshkumar, P.A., 2006. Methotrexate loaded solid lipid nanoparticles (SLN) for effective treatment of carcinoma. *J. Nanosci. Nanotechnol.* 6 (9–10), 2991–2995.
- Rupp, R., Rosenthal, S.L., Stanberry, L.R., 2007. VivaGel (SPL7013 Gel): a candidate dendrimer–microbicide for the prevention of HIV and HSV infection. *Int. J. Nanomed.* 2 (4), 561–566.
- Sanna, V., Gavini, E., Cossu, M., Rassu, G., Giunchedi, P., 2007. Solid lipid nanoparticles (SLN) as carriers for the topical delivery of econazole nitrate: in-vitro characterization, ex-vivo and in-vivo studies. *J. Pharm. Pharmacol.* 59 (8), 1057–1064.
- Sano, N., Wang, H., Chhowalla, M., Alexandrou, I., Amaratunga, G.A.J., 2001. Synthesis of carbon 'onions' in water. *Nature* 414 (6863), 506–507.
- Sarmiento, B., Martins, S., Ferreira, D., Souto, E.B., 2007. Oral insulin delivery by means of solid lipid Nanoparticles. *Int. J. Nanomed.* 2 (4), 743–749.
- Schiffelers, R., Storm, G., Bakker-Woudenberg, I., 2001. Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. *J. Antimicrob. Chemother.* 48 (3), 333–344.
- Schumacher, I., Margalit, R., 1997. Liposome-encapsulated ampicillin: physicochemical and antibacterial properties. *J. Pharm. Sci.* 86 (5), 635–641.
- Schumann, H., Wassermann, B.C., Schutte, S., Velder, J., Aksu, Y., Krause, W., 2003. Synthesis and characterization of water-soluble tin-based metal dendrimers. *Organometallics* 22 (10), 2034–2041.
- Schuster, D.I., Wilson, S.R., Kirschner, A.N., Schinazi, R.F., Schluter-Wirtz, S., Tharnish, P., Barnett, T., Ermoloeff, J., Tang, J., Brettreich, M., Hirsch, A., 2000. Evaluation of the anti-HIV potency of a water-soluble dendrimeric fullerene. *Proc. Electrochem. Soc.* 9, 267–270.
- Serpe, L., Catalano, M.G., Cavalli, R., Ugazio, E., Bosco, O., Canaparo, R., Muntoni, E., Frairia, R., Gasco, M.R., Eandi, M., Zara, G.P., 2004. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. *Eur. J. Pharm. Biopharm.* 58 (3), 673–680.
- Sijbesma, R., Srdanov, G., Wudl, F., Castoro, J.A., Wilkins, C., Friedman, S.H., DeCamp, D.L., Kenyon, G.L., 1993. Synthesis of a fullerene derivative for the inhibition of HIV enzymes. *J. Am. Chem. Soc.* 115 (15), 6510–6512.
- Silva, A.C., Santos, D., Ferreira, D.C., Souto, E.B., 2009. Minoxidil-loaded nanostructured lipid carriers (NLC): characterization and rheological behaviour of topical formulations. *Pharmazie* 64 (3), 177–182.
- Slater, T.F., Cheeseman, K.H., Ingold, K.U., 1985. Carbon tetrachloride toxicity as a model for studying free-radical mediated liver injury. *Philos. Trans. R. Soc. Lond. B: Biol. Sci.* 311 (1152), 633–645.
- Smith, A.M., Dave, S., Nie, S., True, L., Gao, X., 2006. Multicolor quantum dots for molecular diagnostics of cancer. *Expert Rev. Mol. Diag.* 6 (2), 231–244.
- Smith, B.R., Heverhagen, J., Knopp, M., Schmalbrock, P., Shapiro, J., Shiomi, M., Moldovan, N.I., Ferrari, M., Lee, S.C., 2007. Localization to atherosclerotic plaque and biodistribution of biochemically derivatized superparamagnetic iron oxide nanoparticles (SPIONs) contrast particles for magnetic resonance imaging (MRI). *Biomed. Microdevices* 9 (5), 719–727.
- Souto, E.B., Müller, R.H., 2005. SLN and NLC for topical delivery of ketoconazole. *J. Microencapsul.* 22 (5), 501–510.
- Souto, E.B., Wissing, S.A., Barbosa, C.M., Müller, R.H., 2004. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. *Int. J. Pharm.* 278 (1), 71–77.
- Spangler, R.S., 1990. Insulin administration via liposomes. *Diabetes Care* 13 (9), 911–922.
- Sparnacci, K., Laus, M., Tondelli, L., Magnani, L., Bernardi, C., 2002. Core-shell microspheres by dispersion polymerization as drug delivery systems. *Macromol. Chem. Phys.* 203 (10–11), 1364–1369.
- Speiser, P., 1990. Lipidnanopellets als Tragersystem für Arzneimittel zur peroralen Anwendung. *European Patent*, EP 0167825.
- Storni, T., Kündig, T.M., Senti, G., Johansen, P., 2005. Immunity in response to particulate antigen-delivery systems. *Adv. Drug Deliv. Rev.* 57 (3), 333–355.
- Svenson, S., Tomalia, D.A., 2005. Dendrimers in biomedical applications – reflections on the field. *Adv. Drug Deliv. Rev.* 57 (15), 2106–2129.
- Takemoto, K., Yamamoto, Y., Ueda, Y., Sumita, Y., Yoshida, K., Niki, Y., 2004. Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis. *J. Antimicrob. Chemother.* 53 (2), 311–317.
- Tamber, H., Johansen, P., Merkle, H.P., Gander, B., 2005. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. *Adv. Drug Deliv. Rev.* 57 (3), 357–376.
- Templeton, A.C., Wuelfing, W.P., Murray, R.W., 2000. Monolayer-protected cluster molecules. *Acc. Chem. Res.* 33 (1), 27–36.
- Thaxton, C.S., Rosi, N.L., Mirkin, C.A., 2005. Optically and chemically encoded nanoparticle materials for DNA and protein detection. *MRS Bull.* 30 (5), 376–380.
- Thomas, T.P., Patri, A.K., Myc, A., Myaing, M.T., Ye, J.Y., Norris, T.D., Baker, J.R., 2004. In vitro targeting of synthesized antibody-conjugated dendrimer nanoparticles. *Biomacromolecules* 5 (6), 2269–2274.
- Thrash, T.P., Cagle, D.W., Alford, J.M., Ehrhardt, G.J., Wright, K., Mirzadeh, S., Wilson, L.J., 1999. Toward fullerene-based radiopharmaceuticals: high-yield neutron activation of endohedral ¹⁶⁵Ho metallofullerenes. *Chem. Phys. Lett.* 308 (3–4), 329–336.
- Tolia, G.T., Choi, H.H., Ahsan, F., 2008. The role of dendrimers in topical drug delivery. *Pharm. Tech.* 32 (11), 88–98.
- Tomalia, D.A., Reyna, L.A., Svenson, S., 2007. Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. *Biochem. Soc. Trans.* 35 (1), 61–67.
- Ung, T., Liz-Marzan, L.M., Mulvaney, P., 1998. Controlled method for silica coating of silver colloids. Influence of coating on the rate of chemical reactions. *Langmuir* 14, 3740–3748.

- Vandamme, T.F., Brobeck, L., 2005. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. *J. Contr. Rel.* 102 (1), 23–38.
- Vemuri, S., Rhodes, C.T., 1995. Preparation and characterization of liposomes as therapeutic delivery systems: a review. *Pharm. Acta Helv.* 70 (2), 95–111.
- Venkateswarlu, V., Manjunath, K., 2004. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. *J. Control Release* 95 (3), 627–638.
- Wang, S., Mamedova, N., Kotov, N.A., Chen, W., Studer, J., 2002. Antigen antibody immunocomplex from CdTe nanoparticle bioconjugates. *Nano Lett.* 2 (8), 817–822.
- Whitemore, M., Li, S., Huang, L., 2001. Liposome vectors for in vivo gene delivery. *Curr. Protoc. Hum. Genet.* 12.8.1–12.8.9.
- Wiener, E.C., Brechbiel, M.W., Brothers, H., Magin, R.L., Gansow, O.A., Tomalia, D.A., Lauterbur, P.C., 1994. Dendrimer-based metal chelates: a new class of MRI contrast agents. *Magn. Reson. Med.* 31 (1), 1–8.
- Wiener, E.C., Konda, S., Shadron, A., Brechbiel, M., Gansow, O., 1997. Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor. *Invest. Radiol.* 32 (12), 748–754.
- Willard, D.M., Carillo, L.L., Jung, J., Van Orden, A., 2001. CdSe-ZnS quantum dots as resonance energy transfer donors in a model protein–protein binding assay. *Nano Lett.* 1 (9), 469–474.
- Williams, R.M., Zipfel, W.R., Webb, W.W., 2001. Multiphoton microscopy in biological research. *Curr. Opin. Chem. Biol.* 5 (5), 603–608.
- Wissing, S.A., Kayser, O., Müller, R.H., 2004. Solid lipid nanoparticles for parenteral drug delivery. *Adv. Drug Deliv. Rev.* 56 (9), 1257–1272.
- Wong, H.L., Rauth, A.M., Bendayan, R.A., Manias, J.L., Ramaswamy, M., Liu, Z., Erhan, S.Z., Wu, X.Y., 2006. New polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. *Pharm. Res.* 23 (7), 1574–1585.
- Xia, Y., Gates, B., Yin, Y., Lu, Y., 2000. Monodispersed colloidal spheres: old materials with new applications. *Adv. Mater.* 12 (10), 693–713.
- Yang, L.J., Li, Y.B., 2006. Simultaneous detection of Escherichia coli O157:H7 and Salmonella Typhimurium using quantum dots as fluorescence labels. *Analyst* 131 (3), 394–401.
- Yang, S.C., Lu, L.F., Cai, Y., Zhu, J.B., Liang, B.W., Yang, C.Z., 1999. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. *J. Contr. Rel.* 59 (3), 299–307.
- Yoo, M.K., Kim, I.Y., Kim, E.M., Jeong, H.J., Lee, C.M., Jeong, Y.Y., Akaike, T., Cho, C.S., 2007. Superparamagnetic iron oxide nanoparticles coated with galactose-carrying polymer for hepatocyte targeting. *J. Biomed. Biotechnol.* 10, 94740.
- Yuki, Y., Kiyono, H., 2003. New generation of mucosal adjuvants for the induction of protective immunity. *Rev. Med. Virol.* 13 (5), 293–310.
- Zhang, L., Granick, S., 2006. How to stabilize phospholipid liposomes (using nanoparticles). *Nano Lett.* 6 (4), 694–698.
- Zhang, L., Pornpattananangkul, D., Hu, C.M.J., Huang, C.M., 2010. Development of nanoparticles for antimicrobial drug delivery. *Curr. Med. Chem.* 17 (6), 585–594.
- Zhu, L., Ang, S., Liu, W.T., 2004. Quantum dots as a novel immunofluorescent detection system for Cryptosporidium parvum and Giardia lamblia. *Appl. Environ. Microbiol.* 70 (1), 597–598.
- Zhuo, R.X., Du, B., Lu, Z.R., 1999. In vitro release of 5-fluorouracil with cyclic core dendritic polymer. *J. Contr. Rel.* 57 (3), 249–257.
- zur Mühlen, A., 1996. Feste Lipid-Nanopartikel mit prolongierter Wirkstoffliberation: Herstellung, Langzeitstabilität, Charakterisierung, Freisetzungverhalten und Mechanismen. Ph.D. thesis, Free University of Berlin.
- zur Mühlen, A., Mehnert, W., 1998. Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles. *Pharmazie* 53, 552–555.
- zur Mühlen, A., Schwarz, C., Mehnert, W., 1998. Solid lipid nanoparticles (SLN) for controlled drug delivery—drug release and release mechanism. *Eur. J. Pharm. Biopharm.* 45 (2), 149–155.
- zur Mühlen, A., von Elverfeldt, D., Bassler, N., Neudorfer, I., Steitz, B., Petri-Fink, A., Hofmann, H., Bode, C., Peter, K., 2007. Superparamagnetic iron oxide binding and uptake as imaged by magnetic resonance is mediated by the integrin receptor Mac-1 (CD11b/CD18): implications on imaging of atherosclerotic plaques. *Atherosclerosis* 193 (1), 102–111.